Table 8.

Meta-analysis of the data from the five studies included in the quantitative analysis for the efficacy primary outcome change in mean of monthly headache days (MHDs) after 3 months of combination treatment with onabotulinumtoxinA and anti-CGRP mAbs.

	OnabotulinumtoxinA + mAb			OnabotulinumtoxinA				Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI
Armanious et al., 2021	14.2	11.5	21	14.2	11.1	35	6.9%	0.00 [−6.14, 6.14]
Blumenfeld et al., 2021	10.3	8	180	12.1	8	246	34.8%	−1.80 [−3.34, −0.26]
Mechtler et al., 2022	11.6	6.3	127	14	6.9	148	34.5%	−2.40 [−3.96, −0.84]
Nandyala et al., 2022	18.2	10.3	48	20.7	9.1	50	14.3%	−2.50 [−6.35, 1.35]
Toni et al., 2021	18.6	9.4	17	27.6	4.8	17	9.6%	−9.00 [−14.02, −3.98]
Total (95% CI)			393			496	100.0%	−2.67 [−4.42, −0.93]

Heterogeneity: Tau² = 1.54; Chi² = 7.81, df = 4 (p = 0.10); I² = 49%; Test for overall effect: Z = 3.01 (p = 0.003).